To determine the differences in outcome in cases of enterococcal bacteremia due to vancomycinresistant organisms, we compared consecutive patients on a liver transplant service who had clinically significant bacteremia due to vancomycin-resistant Enterococcus faecium (VREF) (n = 54) with a contemporaneous cohort of patients who had vancomycin-susceptible E. faecium (VSEF) bacteremia (n = 48). VREF bacteremia occurred significantly later in the hospitalization than did VSEF bacteremia (43 days vs. 24 days, respectively;P < .01);in addition, VREF was more frequently the sole blood pathogen isolated (91% of patients) than was VSEF (56% of patients) (P = .0002). Invasive interventions for intraabdominal and intrathoracic infection were required more often in the VREF cohort than in the VSEF cohort (34 of 45 patients vs. 20 of 41 patients, respectively; P = .01). Vancomycin resistance more frequently resulted in recurrent bacteremia (22 of 54 patients infected with VREF vs. 7 of 48 patients infected with VSEF; P = .006), persistent isolation of Enterococcus species at the primary site (27 of 33 patients infected with VREF vs. 7 of 18 patients infected with VSEF; P = .005), and endovascular infection (4 patients infected with VREF vs. none infected with VSEF). The decrement in patient survival, as measured from the last bacteremic episode, was greater in the VREF cohort (P = .02). Vancomycin resistance, shock, and liver failure were independent risk factors for Enterococcus-associated mortality. Higher rates of refractory infection, serious morbidity, and attributable death occurred in the VREF cohort and were partially mediated by the lack of effective antimicrobial therapy.
The incidence of infection due to strains of Enterococcus with high-level resistance to vancomycin and teicoplanin has increased dramatically since 1986, when the first cases were recognized [1] [2] [3] [4] [5] . It is not surprising that these infections have usually occurred in immunocompromised or debilitated patients after prolonged hospitalization and treatment with broadspectrum antibiotics [5] [6] [7] [8] . The addition of vancomycin resistance to the other intrinsic and acquired forms of resistance in enterococci has resulted in the elimination of all medical treatment options for serious infections with these organisms and has contributed to the emergence of a "post-antibiotic era" with projected increases in morbidity, mortality, and medical costs [9, 10] .
Therapeutic alternatives with novel combinations of approved antibiotics or unapproved agents have been reported but lack in vitro bactericidal activity and/or proven clinical efficacy for treatment of serious enterococcal infection [11] [12] [13] [14] [15] [16] [17] .
The Enterococcus is now the third most common nosocomial bloodstream pathogen; however, the degree of morbidity and mortality attributable to the organism remains controversial [18, 19] . Confounding variables, which are either biological (e.g., concomitant underlying disease, variable severity of illness, and polymicrobial infection) or methodological (e.g., variable definitions of clinical significance and associated mortality), add to the complexity of this problem. The development of vancomycin resistance in enterococci enabled us to compare the outcomes in cases of medically treatable and untreatable enterococcal infection. We describe 102 patients with bacteremia due either to vancomycin-resistant Enterococcus faecium (VREF) or vancomycin-susceptible E. faecium (VSEF).
Methods
Description of the VREF Outbreak All patients were hospitalized at the University of Pittsburgh Medical Center (Pittsburgh), an 850-bed academic medical facility. The liver transplantation service at the Medical Center occupies four eight-bed intensive care units and 80 beds on other floors; the patients are either awaiting liver transplantation or have received a liver transplant. VREF was first isolated in March 1991 from the wound of a liver transplant recipient. Susceptibility testing showed high-level vancomycin resistance ern 1996; 22 (April) (MIC, >64 j.lg/mL); the MIC of teicoplanin for the organism was >8 j.lg/mL, consistent with the VanA phenotype. Subsequent VREF isolates were recovered with increasing frequency from blood, bile, urine, and other clinical specimens and were predominantly confined to the liver transplantation service. Inverted pulsed field gradient electrophoresis with restriction fragment length polymorphism analysis of 188 VREF isolates (blood and nonblood specimens) from 83 patients during the first 12 months of the outbreak demonstrated two dominant clones of VREF, consistent with a high rate of cross-transmission (W. Wagener, unpublished data). Use of a vanA oligonucleotide probe demonstrated hybridization with chromosomal, but not plasmid, DNA. Resistance in these isolates could not be induced or eradicated, and mating experiments revealed no transfer of resistance [20] .
Bacteriologic Methods
Blood for cultures was obtained by means of sterile venipuncture; 10-15 mL of blood was inoculated into BACTEC 460 6A (aerobic) and 16T (anaerobic) bottles (Becton-Dickinson, Towson, MD) between October 1989 and June 1992 and, subsequently, into BacT/Alert bottles (Organon Teknika, Durham, NC). Enterococci were identified on the basis of the following characteristics: growth on sheep blood agar, on bileesculin agar, and in 6.5% sodium chloride; growth at 45°C; lack of gas production from glucose; and hydrolysis of pyrrolidonyl-B-naphthylamide. The organisms were identified to the species level on the basis of arginine hydrolysis, motility, and carbohydrate fermentation [21] .
Antibiotic susceptibility testing of nonblood isolates was performed by means of the disk diffusion method with use of Mueller-Hinton medium. The MICs for blood isolates were determined by microbroth dilution with standard breakpoints [22] . High-level resistance to gentamicin (MIC,~500 j.lg/mL) was determined with use of Mueller-Hinton medium or brainheart infusion medium by established methods [23] . Nitrocefin disks (Cefinase; BBL Microbiology Systems, Cockeysville, MD) were used to detect ,B-lactamase production.
Patient Population
VREF bacteremia cases. Over a 42-month period (March 1991 to September 1994), information on all patients on the liver transplantation service who had had VREF bloodstream isolates recovered was prospectively recorded in a computerized data base. Data on underlying diseases, dates of hospital admission and liver transplantation, the presence of shock and other concomitant signs of organ failure, radiological studies, all culture and antibiotic-susceptibility results, dates of hospital discharge or in-hospital death, and autopsy results, if available, were collected. Data on the type and duration of antibiotic therapy, percutaneous or surgical drainage, surgical reconstructions, or retransplantation were also recorded.
VSEF bacteremia cases.
Liver transplantation service patients with VSEF bloodstream isolates were retrospectively identified through queries of the Medical Center's computerized microbiological data base for the period November 1989 to September 1994. An MIC of~8 j.lg/mL, determined by macrobroth dilution, indicated susceptibility of the isolates to vancomycin. The same data as those collected for the patients with VREF bacteremia were retrospectively collected through review of the clinical records and the microbiological data base.
Definitions
Clinically significant bacteremia was defined as the presence of E. faecium in two or more blood culture sets or as the presence of E. faecium in one blood culture set and at a concomitant site of infection, as demonstrated by clinical, radiological, or histopathologic evidence. Enterococcus-associated mortality was defined either as death after a blood culture was found to be positive in association with clinical signs (i.e., fever or hypothermia, shock, or purulent drainage) and specific laboratory findings (i.e., leukocytosis, a left shift, or persistent isolation of E. faecium) indicating active enterococcal infection or as histopathological and microbiological evidence of enterococcal infection at autopsy.
Renal failure was defined as a serum creatinine level of > 2 mg/dL or the need for hemodialysis. Liver failure was defined as the presence of cirrhosis or necrosis on histopathologic examination of a biopsy specimen or as a serum bilirubin level of >4 mg/dL and a prothrombin time of > 15 seconds. Shock was defined as systolic blood pressure of <90 mm Hg or dependence on vasopressor agents.
Statistical Methods
For categorical variables, proportions were compared with use of the X 2 test with Yates' correction or with use of Fisher's exact test, depending on the sample size. Continuous variables were analyzed with the Student's t-test or the Mann-Whitney test, depending on sample distribution. Kaplan-Meier survival curves were used to analyze mortality trends, and the results were compared by log-rank analysis. A Cox proportional hazards model was used to analyze the independent risk related to multiple variables for Enterococcus-associated mortality. A two-tailed P value of <.05 was considered significant.
Results
Incidence ofbacteremia due to VREF and VSEF. Fifty-six patients had at least one blood culture positive for VREF. Fiftyfour (96%) of these patients met the definition of clinically significant VREF bacteremia. VSEF bacteremia was associated with a lower rate of clinical significance; 48 (80%) of 60 patients with VSEF bacteremia fulfilled the same criteria. The enterococcal bacteremia was significantly longer for patients in the VREF cohort than for those in the VSEF cohort (43 days vs. 24 days, respectively; P < .01). Hepatocellular disease (e.g., Laennec's cirrhosis or chronic and acute viral hepatitis) was present more frequently than was cholestatic disease (e.g., sclerosing cholangitis, primary biliary cirrhosis, or hepatobiliary tumors) in both cohorts. Excluding the six patients with an unknown primary source of infection in each group, intraabdominal infection predominated in both the VREF group (42 of 48 patients; 88%) and the VSEF group (41 of 42 patients; 98%). The most common primary abdominal sites of infection were the peritoneal space and the biliary tract in both the VREF and VSEF cohorts (table 2). The precipitating cofactors for intraabdominal infection were similar in both groups and included a bile leak (VREF group, 3 patients; VSEF group, 2); stenosis or obstruction of the bile duct (VREF group, 4; VSEF group, 10); a perforated viscus (VREF group, 4; VSEF group, 3); and stenosis or thrombosis of the hepatic artery (VREF group, 6; VSEF group, 8). The occurrence of intraabdominal infection without an obvious precipitating cofactor was more common in the VREF group (25 of 42 patients) than in the VSEF group (18 of 41 patients) (P = .1), a difference that was not statistically significant.
Intrathoracic infection was associated with bacteremia in only three VREF patients; all had infections of the pleural space. One or more copathogens were cultured from the blood of five VREF patients (9%), compared with 21 VSEF patients (44%) (P = .0002). The most common bloodstream copathogens were enteric facultative gram-negative bacilli (VREF group, 1 patient; VSEF group, 13 patients); Pseudomonas aeruginosa (VREF group, 1; VSEF group, 1), Enterococcus faecalis (VREF group, none; VSEF group, 3), Staphylococcus aureus (VREF group, 3; VSEF group, 4), and Candida species (VREF group, none; VSEF group, 2).
Antibiotic susceptibility results. The antimicrobial susceptibilities of all blood isolates are summarized in table 3. Forty percent of VSEF isolates were susceptible to ampicillin, and 81% of VSEF isolates were susceptible to high-level gentamicin; 39% of these isolates were susceptible to both drugs. Tests for ,B-Iactamase production were uniformly negative for all isolates. A temporal trend in terms of susceptibility to ciprofloxacin was observed for VREF isolates: those from all but 3 of the first 22 patients (months 1-19) were susceptible (MIC, <2 j.lg/mL) or intermediately susceptible (MIC, 2-4 j.lg/mL), while those from the next 32 patients (months 20-42) were all resistant.
Eleven VREF blood isolates each were tested against novobiocin (Upj000, Kalamazoo, MI) and quinupristin/dalfopristin (Rhone-Poulenc Rorer, Collegeville, PA), an investigational antibiotic in the streptogramin class. All isolates were susceptible to both drugs (novobiocin MIC, 0.5 -2 j.lg/mL; quinupristin/ dalfopristin MIC, 0.25-0.50 j.lg/mL); however, MBC determinations failed to demonstrate bactericidal activity with either drug. Repeated susceptibility testing of VREF isolates during 19 * Fifty-one patients received antibiotics, and three did not (P = NS).
t Forty-six patients received antibiotics, and two did not (P = NS). t Antibiotics were received from diagnosis of enterococcal bacteremia through the subsequent 21 days.
§ Dosage, 500 mg every 6 hours via nasogastric tube. II Dosage, 7.5 mglkg iv every 8 hours. ** Excluding retransplantation; 20 of the 23 VREF patients underwent the procedure at least twice, as did 6 of the 10 VSEF patients.
against the enterococcal isolate-either vancomycin (n = 19) or an aminopenicillin (n = 1). Treatment with oral novobiocin and intravenous ciprofloxacin (n = 11) or intravenous quinupristin/dalfopristin (n = 11) was initiated after VREF bacteremia was diagnosed. Peak serum inhibitory concentration for patients treated with quinupristin/dalfopristin showed inhibitory activity (serum dilution range, 1:4-1 :512) but not bactericidal activity.
Invasive interventions (percutaneous drainage, surgery, or both) were performed more frequently for patients with intraabdominal and intrathoracic infections due to VREF (34 of 45 patients) than for those with infections due to VSEF (20 of 41) (P = .01; table 3). One or more percutaneous drainage procedures were performed as primary management of VREFinfected foci in 11 patients. However, these procedures were unsuccessful in 10 of the patients as demonstrated by persistent bacteremia and/or continued infection at the primary site in association with systemic signs of infection. In contrast, treatment by means of percutaneous drainage was successful in 9 of 10 patients in the VSEF cohort. Surgical intervention (excluding retransplantation) was used as the initial treatment more often for VREF infections than for VSEF infection (23 of 34 patients vs. 10 of 20 patients, respectively; P = .02). Two or more laparotomies were performed on 20 patients with VREF bacteremia and six with VSEF bacteremia. In both groups, 11 (23) 19 (40) A 4-year (1989-1993) National Nosocomial Infection Surveillance study found significantly higher mortality (36.6%) among patients with bacteremia due to VREF than among those with bacteremia due to VSEF (13.6%) (P < .0001) [5] . Our study confirms those findings and expands on them by providing defined criteria and comorbidity data that allowed us to analyze the relation between enterococcal bacteremia and outDiscussion endocarditis other than the presence of pulmonary artery catheters during hospitalization. Two additional patients developed mycotic aneurysms: in one patient, the aneurysm was located at the vascular anastomosis between the liver graft and the hepatic artery, and in the other, it was located at the anastosmosis between the graft and the portal vein. The first patient's aneurysm was discovered at the time of repeated liver transplantation, and the other's was discovered at autopsy.
Refractory hypotension due to sepsis and/or multisystem organ failure were the major clinical manifestations leading to death in both groups. In-hospital mortality and Enterococcusassociated mortality were both significantly higher among patients with bacteremia due to VREF than among those with bacteremia due to VSEF. The decrement in patient survival related to enterococcal bacteremia was measured from the first and last episodes of enterococcal bacteremia (figure 1). Associated mortality rates were nearly identical for the two groups during the first 2 weeks after the initial bacteremic episode. However, the deleterious effect of recurrent VREF bacteremia was evidenced by the shorter interval from the last positive blood culture to death; the cumulative 30-day survival trend, measured from the last bacteremic episode, was significantly lower for the VREF group (P = .02) but was not statistically significant when measured from the first bacteremic episode (P = .1). Evidence of active enterococcal infection-predominantly visceral abscesses or peritonitis-was present in 11 of 14 autopsied patients in the VREF group, and Enterococcus was the only pathogen recovered in seven autopsies. Distant metastatic VREF infection, which involved the bone marrow, kidneys, and tricuspid valve (see above), was unexpectedly found during each of three autopsies.
We combined 12 clinical and microbiological variables potentially related to Enterococcus-associated mortality into a logistic regression model to assess the independent contribution of each cofactor to mortality among our patients. The mortality association was expressed as an RR with a 95% CI. Vancomycin resistance (RR, 3.47; CI, 1.47-8.19), shock (RR, 4.34; CI, 1.79-18.5), and liver failure (RR, 3.14; CI, 1.52-6.50) were associated with an increased risk of death. No independent association with mortality was found for age (>50 years), renal failure, polymicrobial infection at the primary site, underlying malignancy, polymicrobial bacteremia, intraabdominal site of infection, duration of hospitalization, surgery within 7 days of the development of bacteremia, or multiple-transplant status.
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I (7) 17 (35) 12 (25) 11 (14) 31 ( sion to the initial bacteremic episode) made it untenable to match them for this important variable; however, length of stay did not result in other major differences between the VREF and VSEF groups. Vancomycin resistance played an independent, critical role in terms of outcome in our study. Enterococcal bacteremia is often a breakthrough event attributed to a gap in broad-spectrum antimicrobial therapy [24, 25] . Indeed, VREF bacteremia exemplifies this phenomenon, as there is no effective antibiotic treatment for it. Postoperative intraabdominal VREF infection may reflect selective microbial growth due to perioperative antibiotic use that results in peritonitis and intraabdominal abscess formation; this effect is suggested by the smaller number of anatomically precipitating factors in patients in the VREF group.
Bacteremia due to VSEF was often polymicrobial, with multiple organisms isolated both at the primary site and in the bloodstream. Conversely, VREF bacteremia was typically monomicrobial, indicating a selective breakthrough effect. The rate of polymicrobial bacteremia for the VREF cohort (9%) was significantly lower than that for the VSEF cohort, and it was lower than the rates demonstrated in other series of enterococcal bacteremia (table 6) [25] [26] [27] [28] [29] [30] [31] [32] [33] . The inability to adequately modify antibiotic coverage to eradicate VREF resulted in protracted tissue infections and bloodstream infections despite the frequent use of drainage procedures.
The development of two cases of endocarditis following well-documented intraabdominal infection with VREF is of special concern. The facts that endocarditis due to high-level aminoglycoside-resistant strains of Enterococcus is refractory when single-agent bacteriostatic therapy is administered and that it has been associated with a high relapse rate with this therapy suggest that the prognosis for VREF endocarditis is quite poor [34] . Our review of all autopsy records of the liver transplantation service at our institution for the years 1988-1994 failed to demonstrate any case of endocarditis due to vancomycin-susceptible Enterococcus species. Moreover, cases of enterococcal endocarditis, occurring both after nosocomial acquisition of the organism and as right-sided disease, are especially uncommon [26, 35] . The prior use of pulmonaryartery catheters in these patients may be a predisposing factor [36] . The new appearance of this complication exclusively in the VREF cohort suggests that protracted enterococcemia was responsible. It is still possible that a virulence factor other than multi drug resistance in our strain(s) could have increased the affinity for cardiac valve tissue. However, there is no definitive experimental or clinical evidence that antibiotic resistance is a surrogate marker for increased adherence or invasive properties [37] .
The closer temporal association between bacteremia and death in the VREF group, as well as the higher frequency of enterococcal infection detected post-mortem in this group, provides direct evidence that refractory enterococcal infection was a major contributor to mortality. The overall mortality rate come and to describe the clinical and bacteriological patterns that vancomycin resistance confers. In the present study, VREF was associated with clinical sequelae that were both more frequent and more severe than those associated with VSEF, in either pure enterococcal infection or polymicrobial infection. Although our study was retrospective and not case controlled, the cohorts were comparable for major outcome-dependent variables; they were predominantly contemporaneous; and they were drawn from the same patient population and institution. Since our study design preselected patients with VREF bacteremia, a longer length of stay before the development of enterococcal bacteremia was an expected finding; acquisition of VREF was purely nosocomial. This finding has been reported by others [6] [7] [8] . The difference between the two groups in terms of length of stay (from admis- (57%) for the VREF group falls within the range of mortality (26%-68%) previously observed among patients with enterococcal bacteremia (table 5) [25] [26] [27] [28] [29] [30] [31] [32] [33] . Although definitions of Enterococcus-associated mortality may vary, the 46% mortality associated with VREF bacteremia in our study was significantly higher than the mortality among our patients in the VSEF cohort and the 7%-19% range observed in five series (table 5) [ 27-29, 31, 33] . It is noteworthy that specific antienterococcal therapy was associated with reduced mortality in four of these studies [25, 26, 29, 33] . The more than threefold increase in risk of Enterococcus-associated death that was attributable to vancomycin resistance indirectly supports the beneficial effect of antienterococcal therapy in the VSEF cohort. There is still diversity of opinion as to the benefits of antienterococcal antibiotic therapy in the surgical population because nonmedical interventions such as closed or open drainage may be curative alone [38] . For enterococcal infections involving a local compromise of host defenses, such as endocarditis and meningitis, optimal management includes a bactericidal combination of a cell-wall active agent (i.e., a ,B-Iactam or glycopeptide) and an aminoglycoside [39] [40] [41] . The need for bactericidal therapy in systemically immunocompromised patients is suggested in the literature; however, even single-agent bacteriostatic therapy has been shown to improve the outcome for patients with clinically significant bloodstream infections. Several studies of vancomycin-susceptible enterococcal bacteremia have indicated an association between poor outcome and the antibiotic resistance pattern or inappropriate antibiotic therapy [29, [42] [43] [44] .
Thus, resistance to glycopeptides should be viewed along the continuum of resistance to penicillin and aminoglycosides with high MIC ranges-all forms of resistance that appear to indirectly augment the opportunistic behavior of enterococci. The immediate consequences of this altered microbial behavior in our immunocompromised patients were prolonged hospitalization and increased morbidity and mortality.
Enterococci are the most prevalent nosocomial pathogens that have such a complete spectrum of resistance to previously effective antibiotics. The prominent effects of complete antibiotic resistance in the Enterococcus, a pathogen with low intrinsic virulence, make the acquisition of comparable resistance by more virulent nosocomial pathogens, such as Staphylococcus aureus and the facultative and aerobic gram-negative bacilli, a sobering prospect. Although prudent use of broad-spectrum antibiotics and institution of aggressive measures to limit nosocomial transmission may reduce the number of bloodstream infections with VREF, the optimal management of established VREF bloodstream infections is unknown. With no effective antibiotic therapy available in the foreseeable future, an even greater reliance on early appropriate invasive interventions in the surgical patient population is warranted. An effective bactericidal antibiotic is urgently needed to serve as an adjunct in the management of surgical infections that fail to respond to aggressive surgical intervention.
